Featured Research

from universities, journals, and other organizations

Adrenaline use in cardiac arrest

Date:
July 26, 2011
Source:
Elsevier
Summary:
Adrenaline has kept its place in cardiac arrest guidelines despite limited evidence for or against its use. The PACA (Placebo versus Adrenaline versus Cardiac Arrest) study provides the best evidence to date supporting the use of adrenaline to treat cardiac arrest.

Adrenaline has kept its place in cardiac arrest guidelines despite limited evidence for or against its use. The PACA (Placebo versus Adrenaline versus Cardiac Arrest) study by Jacobs and colleagues, soon to be published in Resuscitation, the official journal of the European Resuscitation Council, provides the best evidence to date supporting the use of adrenaline to treat cardiac arrest.

In this single-centre double blind study, 601 out-of-hospital cardiac arrest victims were randomized to receive either placebo (0.9% sodium chloride) or adrenaline during advanced life support. Data available from 534 patients (262 placebo vs. 272 adrenaline) showed no difference in the primary end study point, survival to hospital discharge, but did show that a spontaneous circulation was restored (in other words the heart was 'restarted') three times more commonly with adrenaline (23.5%) than with saline placebo (8.4%).

Professor Jacobs commented, "Our study highlights the significant challenges in undertaking randomized trials in cardiac arrest, particularly when it involves accepted but unproven therapy. Although we were unable to demonstrate that adrenaline improved the chance of surviving to hospital discharge, adrenaline did increase the likelihood of restoring circulation following cardiac arrest."

Editor-in-Chief of Resuscitation, Dr Jerry Nolan said, "The authors are to be congratulated for undertaking this important study despite the very challenging factors that are inevitable in the out-of-hospital environment. This is the first placebo controlled trial in human cardiac arrest that has shown short term survival benefit for adrenaline."


Story Source:

The above story is based on materials provided by Elsevier. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ian G Jacobs, Judith C Finn, George A Jelinek, Harry F Oxer, Peter L Thompson. Effect of adrenaline on survival in out-of-hospital cardiac arrest: a randomised double-blind placebo-controlled trial. Resuscitation, 2011; DOI: 10.1016/j.resuscitation.2011.06.029

Cite This Page:

Elsevier. "Adrenaline use in cardiac arrest." ScienceDaily. ScienceDaily, 26 July 2011. <www.sciencedaily.com/releases/2011/07/110726093154.htm>.
Elsevier. (2011, July 26). Adrenaline use in cardiac arrest. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/07/110726093154.htm
Elsevier. "Adrenaline use in cardiac arrest." ScienceDaily. www.sciencedaily.com/releases/2011/07/110726093154.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins